Continuous assessment of clinical course, outcome and resources in patients treated for Post-COVID

Conditions

U09.9 U07.9

Veronica Ober, Felix Völk, Julia Sbierski‐Kind, Eva Grüner, Renate Stirner et al. (13 authors)

The Journal of Infectious Diseases2025-04-241 citations

10.1093/infdis/jiaf211

Characterization of cognitive symptoms in post COVID-19 patients

Michael Ruzicka, Simone Sachenbacher, Fides Heimkes, Aline Olivia Uebleis, Susanne Karch et al. (21 authors)

European Archives of Psychiatry and Clinical Neuroscience2024-05-1313 citations

10.1007/s00406-024-01821-z

Substantial differences in perception of disease severity between post COVID-19 patients, internists, and psychiatrists or psychologists: the Health Perception Gap and its clinical implications.

Ruzicka M, Ibarra Fonseca GJ, Sachenbacher S, Heimkes F, Grosse-Wentrup F, Wunderlich N, Benesch C, Pernpruner A, Valdinoci E, Rueb M, Uebleis AO, Karch S, Bogner J, Mayerle J, von Bergwelt-Baildon M, Subklewe M, Heindl B, Stubbe HC, Adorjan K.

2023-11-136 citations

10.1007/s00406-023-01700-z

Interventions

Group 1: Patients with COVID-19 sequelae lasting at least 4 weeks with documented SARS-CoV-2 infection within the past 6 months

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Patients with COVID-19 sequelae lasting at least 4 weeks with documented SARS-CoV-2 infection within the past 48 months. (2) Persons who were treated for acute infections other than COVID-19 or who had COVID-19 within the past 48 month without ongoing signs and symptoms of COVID-19 as control group. (3) All participants need to be of full age.

Exclusion criteria

Exclusion criteria: (1) Patients presenting in the complete recovery phase of PCS at inclusion or (2) obvious alternative explanations for the PCS-associated signs and symptoms or (3) onset of PCS-associated signs and symptoms before acute COVID-19.

Design outcomes

Primary

Measure	Time frame
(1) Quality of life as measured by validated and standardized assessment tools (WHOQOL-BREF, PROMIS-10) (2) PCS-associated deterioration (e.g. need for hospitalization, increase in medical interventions or medical visits) (3) resolution of post-COVID-syndrome	—

Secondary

Measure	Time frame
(1) Overall survival (2) Occurence of life-threatening complications (3) Time to deterioration	—

Countries

Germany

Contacts

Public ContactHans Christian Stubbe

LMU Klinikum

hstubbe@med.lmu.de089440074994

Outcome results

None listed